<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04668703</url>
  </required_header>
  <id_info>
    <org_study_id>Yumeng Shi</org_study_id>
    <nct_id>NCT04668703</nct_id>
  </id_info>
  <brief_title>Prophylactic Effect of Conbercept Intravitreal Injection at the Conclusion of Cataract Surgery for Diabetic Macular Edema</brief_title>
  <official_title>Prophylactic Effect of Conbercept Intravitreal Injection at the Conclusion of Cataract Surgery for Diabetic Macular Edema in Cataract Patients With Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye &amp; ENT Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eye &amp; ENT Hospital of Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic macular edema (DME) is an important cause of central vision impairment among people&#xD;
      with diabetic retinopathy (DR), which can have a significant adverse effect on daily&#xD;
      activities and quality of life. Diabetic patients with preexisting DME are at increased risk&#xD;
      of worsening edema following cataract surgery. Previous studies also reported progression of&#xD;
      DR after cataract surgery. Clinically significant DME is now classified into center-involved&#xD;
      DME (CI-DME) and non center-involved DME (non-CI DME). Randomized clinical trials have&#xD;
      established intravitreal antivascular endothelial growth factor (VEGF) therapy as first-line&#xD;
      treatment for visual impairment from CI-DME and studies have addressed the influence of&#xD;
      anti-VEGF therapy among patients with DME undergoing cataract surgery. However, for patients&#xD;
      with non-CI DME before cataract surgery, whether anti-VEGF therapy is necessary at the end of&#xD;
      surgery to prevent CI-DME is still clinically controversial. In order to evaluate the&#xD;
      prophylactic effect of Conbercept (a recombinant fusion protein with high affinity to all&#xD;
      VEGF isoforms and PIGF) intravitreal injection at the conclusion of cataract surgery for DME&#xD;
      in patients with DR, the investigators will prospectively recruit 40 cataract patients with&#xD;
      DR and non-CI DME and randomly assign these subjects into the study group (combined cataract&#xD;
      surgery and intravitreal Conbercept injection, 20 cases) and the control group (cataract&#xD;
      surgery alone, 20 cases). The primary outcomes include mean changes in central retinal&#xD;
      thickness (CRT) and in diabetic retinopathy severity score (DRSS). The secondary outcomes&#xD;
      include changes in best corrected visual acuity (BCVA), foveal avascular zone (FAZ), retinal&#xD;
      vessel density (VD), the aqueous concentrations of VEGF, PIGF, interleukin- (IL-) 2, IL-5,&#xD;
      IL-6, and IL-8.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in central retinal thickness (CRT) with optical coherence tomography (OCT)</measure>
    <time_frame>Baseline, 1 month and 3 month after operation</time_frame>
    <description>to compare the mean change from baseline of CRT between treatment group and control group at month 1 and 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in diabetic retinopathy severity score (DRSS)</measure>
    <time_frame>Baseline, 1 month and 3 month after operation</time_frame>
    <description>to compare the mean change from baseline of DRSS between treatment group and control group at month 1 and 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in best corrected visual acuity (BCVA)</measure>
    <time_frame>Baseline, 1 month and 3 month after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in foveal avascular zone (FAZ) with optical coherence tomography angiography (OCTA)</measure>
    <time_frame>Baseline, 1 month and 3 month after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in retinal vessel density (VD) with optical coherence tomography angiography (OCTA)</measure>
    <time_frame>Baseline, 1 month and 3 month after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the aqueous concentrations of VEGF, PIGF, interleukin- (IL-) 2, IL-5, IL-6, and IL-8</measure>
    <time_frame>Baseline, 1 week, 1 month and 3 month after operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Cataract Diabetic</condition>
  <arm_group>
    <arm_group_label>combined cataract surgery and intravitreal Conbercept injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive conbercept injections at a dose of 0.5 mg/eye at the conclusion of cataract surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cataract surgery alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will undergo cataract surgery by phacoemulsification and intraocular lens implantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conbercept intravitreal injection</intervention_name>
    <description>intravitreal injection of 0.5 mg conbercept at the conclusion of cataract surgery</description>
    <arm_group_label>combined cataract surgery and intravitreal Conbercept injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients sign informed consent, and are willing and able to comply with all the&#xD;
             follow-ups&#xD;
&#xD;
          -  Age ≥ 18 years , both genders&#xD;
&#xD;
          -  Diagnosis of type 1 or type 2 diabetes mellitus&#xD;
&#xD;
          -  Serum HbA1c ≤ 10%&#xD;
&#xD;
          -  Patients with a diagnosis of DR (ETDRS 35-53) and cataract&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CI-DME&#xD;
&#xD;
          -  Any other ocular disorder in the study eye that may cause macular edema excluded the&#xD;
             diabetic retinopathy&#xD;
&#xD;
          -  History of allergic reaction to fluorescein, protein agents for diagnosis or therapy,&#xD;
             or more than 2 drug or nondrug factors, or concomitant allergic diseases&#xD;
&#xD;
          -  Received anti- VEGF treatment (including intravitreal injection or systematic&#xD;
             application) within three months prior to enrollment&#xD;
&#xD;
          -  History of panretinal laser photocoagulation (PRP) in the study eye 6 months prior to&#xD;
             enrollment, or possibly need panretinal photocoagulation of the study eye during the&#xD;
             study&#xD;
&#xD;
          -  Intraocular conventional surgery within the past three months&#xD;
&#xD;
          -  Traumatic cataract or congenital bilateral cataract in the study eye&#xD;
&#xD;
          -  Active ocular or periocular infection in either eye&#xD;
&#xD;
          -  Iris neovascularization in the study eye&#xD;
&#xD;
          -  Uncontrolled glaucoma, or history of glaucoma surgery&#xD;
&#xD;
          -  Aphakia in the study eye&#xD;
&#xD;
          -  History of vitrectomy in the study eye&#xD;
&#xD;
          -  The density of corneal endothelial cells is lower than 2000/mm2&#xD;
&#xD;
          -  Patients with uncontrolled hyperglycemia, or Hemoglobin A1C (HbA1c) ≥10.0%, or under&#xD;
             hemodialysis, or started insulin usage within the last 4 months, or expected to start&#xD;
             insulin use for hyperglycemia control in the next 4 months&#xD;
&#xD;
          -  Any surgical contraindications&#xD;
&#xD;
          -  Uncontrolled Blood Pressure&#xD;
&#xD;
          -  Myocardial infarction, heart failure, stroke, or transient ischemic attack within one&#xD;
             month&#xD;
&#xD;
          -  Renal Failure&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Participation in another simultaneous medical investigator or trial&#xD;
&#xD;
          -  Other situations where the researcher judges that the patient is not suitable for&#xD;
             inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Yang, MD, ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Eye &amp; ENT Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Yang, MD, ph.D.</last_name>
    <phone>+8613671632525</phone>
    <email>jin_er76@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yumeng Shi, MD</last_name>
    <phone>+8619945616479</phone>
    <email>mengmenger123@163.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Glassman AR, Wells JA 3rd, Josic K, Maguire MG, Antoszyk AN, Baker C, Beaulieu WT, Elman MJ, Jampol LM, Sun JK. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology. 2020 Sep;127(9):1201-1210. doi: 10.1016/j.ophtha.2020.03.021. Epub 2020 Mar 29.</citation>
    <PMID>32402554</PMID>
  </reference>
  <reference>
    <citation>Zhang J, Liang Y, Xie J, Li D, Hu Q, Li X, Zheng W, He R. Conbercept for patients with age-related macular degeneration: a systematic review. BMC Ophthalmol. 2018 Jun 15;18(1):142. doi: 10.1186/s12886-018-0807-1. Review.</citation>
    <PMID>29902977</PMID>
  </reference>
  <reference>
    <citation>Relhan N, Flynn HW Jr. The Early Treatment Diabetic Retinopathy Study historical review and relevance to today's management of diabetic macular edema. Curr Opin Ophthalmol. 2017 May;28(3):205-212. doi: 10.1097/ICU.0000000000000362. Review.</citation>
    <PMID>28151747</PMID>
  </reference>
  <reference>
    <citation>Peterson SR, Silva PA, Murtha TJ, Sun JK. Cataract Surgery in Patients with Diabetes: Management Strategies. Semin Ophthalmol. 2018;33(1):75-82. doi: 10.1080/08820538.2017.1353817. Epub 2017 Nov 16. Review.</citation>
    <PMID>29144826</PMID>
  </reference>
  <reference>
    <citation>Grzybowski A, Kanclerz P, Huerva V, Ascaso FJ, Tuuminen R. Diabetes and Phacoemulsification Cataract Surgery: Difficulties, Risks and Potential Complications. J Clin Med. 2019 May 20;8(5). pii: E716. doi: 10.3390/jcm8050716. Review.</citation>
    <PMID>31137510</PMID>
  </reference>
  <reference>
    <citation>Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, Boyer DS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Vitti R, Berliner AJ, Zeitz O, Metzig C, Holz FG. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology. 2016 Nov;123(11):2376-2385. doi: 10.1016/j.ophtha.2016.07.032. Epub 2016 Sep 17.</citation>
    <PMID>27651226</PMID>
  </reference>
  <reference>
    <citation>Ip MS, Zhang J, Ehrlich JS. The Clinical Importance of Changes in Diabetic Retinopathy Severity Score. Ophthalmology. 2017 May;124(5):596-603. doi: 10.1016/j.ophtha.2017.01.003. Epub 2017 Mar 8.</citation>
    <PMID>28284785</PMID>
  </reference>
  <reference>
    <citation>Dhoot DS, Baker K, Saroj N, Vitti R, Berliner AJ, Metzig C, Thompson D, Singh RP. Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID. Ophthalmology. 2018 Jan;125(1):51-56. doi: 10.1016/j.ophtha.2017.06.029. Epub 2017 Jul 29.</citation>
    <PMID>28764888</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

